drug_type
RELEVANT_DRUG
intervention_type
Gene-edited cellular immunotherapy
drug_description
Donor-derived T lymphocytes engineered by CRISPR genome editing to disrupt the endogenous T-cell receptor (and potentially other loci) and to express a tumor antigen–specific chimeric antigen receptor; intended for off-the-shelf use to reduce graft-versus-host risk and mediate cytotoxic killing of antigen-expressing malignant cells via CAR signaling and T-cell effector pathways.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Donor-derived T lymphocytes are CRISPR-edited to disrupt the endogenous T-cell receptor (and potentially other loci) and engineered to express a tumor antigen–specific chimeric antigen receptor. The CAR redirects T cells to bind the target antigen and activate via CD3ζ/costimulatory signaling, leading to cytotoxic killing of antigen-expressing malignant cells through perforin/granzyme release and cytokine-mediated effects. TCR knockout enables off-the-shelf use and reduces graft-versus-host disease risk.
drug_name
Allogeneic CRISPR-edited CAR T cells
nct_id_drug_ref
NCT06208878